Drug resistant integrase mutants cause aberrant HIV integrations

BACKGROUND: HIV-1 integrase is the target for three FDA-approved drugs, raltegravir, elvitegravir, and dolutegravir. All three drugs bind at the active site of integrase and block the strand transfer step of integration. We previously showed that sub-optimal doses of the anti-HIV drug raltegravir ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Varadarajan, Janani, McWilliams, Mary Jane, Mott, Bryan T., Thomas, Craig J., Smith, Steven J., Hughes, Stephen H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041404/
https://www.ncbi.nlm.nih.gov/pubmed/27682062
http://dx.doi.org/10.1186/s12977-016-0305-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041404/
https://www.ncbi.nlm.nih.gov/pubmed/27682062
http://dx.doi.org/10.1186/s12977-016-0305-6

Ejemplares similares